Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations

INTRODUCTION: Tyrosine kinase inhibitors gefitinib, erlotinib, and afatinib have been compared with chemotherapy as first-line therapies for patients with advanced non–small-cell lung cancer harboring epidermal growth factor receptor–activating mutations. This meta-analysis compares gefitinib, erlot...

Descripción completa

Detalles Bibliográficos
Autores principales: Haaland, Benjamin, Tan, Pui San, de Castro, Gilberto, Lopes, Gilberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4219539/
https://www.ncbi.nlm.nih.gov/pubmed/24787964
http://dx.doi.org/10.1097/JTO.0000000000000156

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4219539/
https://www.ncbi.nlm.nih.gov/pubmed/24787964
http://dx.doi.org/10.1097/JTO.0000000000000156

Ejemplares similares